Inclusion Criteria:

          -  Male or female subjects ≥ 18 years of age

          -  Histologic or cytologic evidence of NSCLC

          -  Known KRAS mutation

          -  The subject must have received appropriate prior therapy

          -  Measurable disease according to RECIST 1.1

          -  An Eastern Cooperative Group (ECOG) performance status ≤ 1

          -  Adequate organ function

          -  Adequate recovery from toxicities related to prior treatments

          -  Agreement to use highly effective method of contraceptive

        Exclusion Criteria:

          -  Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy

          -  History of prior malignancy, with the exception of curatively treated malignancies

          -  Major surgery within 4 weeks (excluding placement of vascular access)

          -  History of treatment with a direct and specific inhibitor of MEK or KRAS

          -  Exposure to strong CYP2C9 and CYP3A4 inhibitors or inducers within 7 days prior to the
             first dose and during the course of therapy

          -  Symptomatic brain metastases requiring steroids or other local interventions.

          -  Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy

          -  Active skin disorder that has required systemic therapy within the past 1 year

          -  History of rhabdomyolysis

          -  Concurrent ocular disorders

          -  Concurrent heart disease or severe obstructive pulmonary disease

          -  Subjects with the inability to swallow oral medications